Published in Int J Radiat Oncol Biol Phys on July 01, 2009
Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer. Cancer (2015) 2.10
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 2.05
Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg (2010) 1.48
Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer (2011) 1.35
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg (2011) 1.24
Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol (2010) 1.18
Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience. Radiat Oncol (2010) 1.16
Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol (2010) 1.11
Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today (2012) 1.02
The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies. Langenbecks Arch Surg (2012) 0.99
Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer. World J Gastroenterol (2011) 0.99
Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis (2012) 0.99
Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol (2011) 0.98
Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis (2011) 0.95
Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis (2010) 0.92
hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy. Int J Colorectal Dis (2012) 0.87
Treatment of locally advanced rectal cancer: controversies and questions. World J Gastroenterol (2012) 0.86
High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis (2011) 0.86
Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol (2015) 0.84
Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg (2015) 0.84
Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy. Cancers (Basel) (2011) 0.83
Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes Chromosomes Cancer (2011) 0.83
DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy. Biomed Res Int (2013) 0.83
Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. Int J Colorectal Dis (2010) 0.82
Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study. Radiat Oncol (2011) 0.82
Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies. Oncologist (2013) 0.81
Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. Eur J Nucl Med Mol Imaging (2013) 0.81
Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer. Cancer Res Treat (2015) 0.81
Role of tumor size in the pre-operative management of rectal cancer patients. BMC Gastroenterol (2010) 0.81
P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer (2014) 0.81
FXYD-3 expression in relation to local recurrence of rectal cancer. Radiat Oncol J (2016) 0.80
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy. Radiat Oncol (2015) 0.80
A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol Ther (2015) 0.80
Radiotherapy response in microsatellite instability related rectal cancer. Korean J Pathol (2013) 0.80
Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. PLoS One (2016) 0.78
Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance. World J Gastroenterol (2013) 0.78
Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Chin J Cancer (2015) 0.78
Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review. Eur J Clin Pharmacol (2015) 0.78
Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. Clin Colorectal Cancer (2012) 0.78
MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int J Mol Sci (2016) 0.78
A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial. Mol Clin Oncol (2016) 0.78
The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer. Int J Colorectal Dis (2014) 0.78
Immunological Landscape and Clinical Management of Rectal Cancer. Front Immunol (2016) 0.77
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol (2011) 0.77
Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. World J Gastrointest Oncol (2014) 0.77
An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget (2015) 0.77
Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy. World J Gastroenterol (2014) 0.76
A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer. Front Oncol (2013) 0.76
XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. Oncotarget (2015) 0.76
YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study. PLoS One (2015) 0.76
Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer. Radiat Oncol J (2016) 0.75
Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer. Br J Cancer (2017) 0.75
Response to chemoradiotherapy and lymph node involvement in locally advanced rectal cancer. World J Gastrointest Surg (2015) 0.75
miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther (2016) 0.75
Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment. BMC Cancer (2010) 0.75
Identification of molecular characteristics induced by radiotherapy in rectal cancer based on microarray data. Oncol Lett (2017) 0.75
Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study. BMC Cancer (2016) 0.75
A prospective study on histone γ-H2AX and 53BP1 foci expression in rectal carcinoma patients: correlation with radiation therapy-induced outcome. BMC Cancer (2015) 0.75
Circadian gene expression predicts patient response to neoadjuvant chemoradiation therapy for rectal cancer. Int J Clin Exp Pathol (2015) 0.75
Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. Radiat Oncol (2013) 0.75
Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma. Oncotarget (2016) 0.75
Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. Oncol Lett (2017) 0.75
Intraoperative staging by surgeons in patients with rectal cancer after preoperative chemoradiation: diagnostic accuracy and prognostic value. J Cancer Res Clin Oncol (2014) 0.75
Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy. Int J Clin Oncol (2015) 0.75
Predictive clinical model of tumor response after chemoradiation in rectal cancer. Oncotarget (2017) 0.75
Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy. Eur J Nucl Med Mol Imaging (2016) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Genomics and drug response. N Engl J Med (2011) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology (2005) 3.58
Risk of pelvic fractures in older women following pelvic irradiation. JAMA (2005) 3.26
A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet (2006) 3.24
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A (2004) 2.37
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther (2009) 2.10
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs (2005) 2.09
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol (2006) 1.94
Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med (2013) 1.89
The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. J Clin Oncol (2009) 1.88
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol (2004) 1.86
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther (2006) 1.82
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol (2008) 1.81
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 1.75
Practice patterns and long-term survival for early-stage rectal cancer. J Clin Oncol (2013) 1.69
Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology (2008) 1.68
Complications associated with neoadjuvant radiotherapy in the multidisciplinary treatment of retroperitoneal sarcomas. Ann Surg Oncol (2006) 1.61
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985) (2003) 1.55
Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol (2005) 1.52
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol (2005) 1.49
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Res (2008) 1.48
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol (2007) 1.46
Is less more? Lessons in radiation schedules in breast cancer. J Natl Cancer Inst (2002) 1.45
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer (2003) 1.41
Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys (2005) 1.40
Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos (2005) 1.38
CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol (2008) 1.36
Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer (2003) 1.36
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics (2011) 1.34
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics (2008) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res (2006) 1.31
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res (2002) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet (2006) 1.28
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys (2002) 1.27
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum (2006) 1.27
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer (2003) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics (2012) 1.23
Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer (2007) 1.21
Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci (2009) 1.21
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol (2004) 1.20
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res (2008) 1.20
Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther (2007) 1.18
Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol (2002) 1.17
PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics (2011) 1.16
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16
PromoLign: a database for upstream region analysis and SNPs. Hum Mutat (2004) 1.15
Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta (2003) 1.15
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn (2009) 1.12
PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat (2005) 1.12
Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet (2005) 1.09
Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics (2004) 1.09
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res (2004) 1.09
Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics (2009) 1.08
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics (2009) 1.07
Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet (2004) 1.07
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res (2010) 1.07
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics (2008) 1.07
The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci (2006) 1.06
Technology evolution: is it survival of the fittest? J Clin Oncol (2010) 1.05
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res (2006) 1.05
Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics (2009) 1.05
SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat (2002) 1.05
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther (2004) 1.04
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother (2010) 1.03
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res (2005) 1.02
Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet (2014) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol (2004) 1.01
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics (2005) 1.00